Revolution Medicines (RVMD) Equity Ratio (2019 - 2026)

Revolution Medicines' Equity Ratio history runs 8 years deep, the most recent figure standing at 0.67 for Q1 2026.

• In Q1 2026, Equity Ratio fell 24.25% year-over-year to 0.67; the TTM figure through Mar 2026 stood at 0.67 (down 24.25% YoY), while the FY2025 annual figure was 0.69, down 21.75% from the prior year.
• Equity Ratio was 0.67 for Q1 2026 at Revolution Medicines, down from 0.69 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.9 in Q1 2024 to a low of 0.67 in Q1 2026.
• Historically, Equity Ratio has averaged 0.83 across 5 years, with a median of 0.85 in 2023.
• The sharpest annual moves came in 2023 and 2026: Equity Ratio rose 9.97% in 2023, then declined 24.25% in 2026.
• A 5-year view of Equity Ratio shows it stood at 0.84 in 2022, then climbed by 4.96% to 0.89 in 2023, then fell by 0.04% to 0.89 in 2024, then retreated by 21.75% to 0.69 in 2025, then fell by 3.94% to 0.67 in 2026.
• The last three Equity Ratio figures came in at 0.67 (Q1 2026), 0.69 (Q4 2025), and 0.71 (Q3 2025), per Business Quant data.